Insider Transactions in Q4 2025 at Quest Diagnostics Inc (DGX)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 25
2025
|
Vicky B Gregg Director |
SELL
Open market or private sale
|
Direct |
1,250
-6.84%
|
$238,750
$191.76 P/Share
|
|
Nov 25
2025
|
J. E. Davis CEO and President |
SELL
Open market or private sale
|
Direct |
55,093
-11.26%
|
$10,577,856
$192.28 P/Share
|
|
Nov 25
2025
|
J. E. Davis CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
55,093
+23.88%
|
$5,233,835
$95.8 P/Share
|
|
Nov 18
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
7,946
-51.34%
|
$1,485,902
$187.35 P/Share
|
|
Nov 18
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,946
+17.21%
|
$1,136,278
$143.9 P/Share
|
|
Nov 05
2025
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
7,143
-5.6%
|
$1,250,025
$175.57 P/Share
|
|
Oct 22
2025
|
Gary M Pfeiffer Director |
SELL
Open market or private sale
|
Direct |
1,482
-4.79%
|
$269,724
$182.4 P/Share
|
|
Oct 21
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15
+0.2%
|
$2,835
$189.08 P/Share
|
|
Oct 21
2025
|
Vicky B Gregg Director |
BUY
Grant, award, or other acquisition
|
Direct |
70
+0.38%
|
$13,230
$189.08 P/Share
|
|
Oct 21
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
15
+0.18%
|
$2,835
$189.08 P/Share
|
|
Oct 21
2025
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Grant, award, or other acquisition
|
Direct |
46
+0.3%
|
$8,694
$189.08 P/Share
|
|
Oct 21
2025
|
Sam Samad Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
68
+0.26%
|
$12,852
$189.08 P/Share
|
|
Oct 21
2025
|
Robert B Carter Director |
BUY
Grant, award, or other acquisition
|
Direct |
6
+0.22%
|
$1,134
$189.09 P/Share
|